Shows
やくめでぃラジオPCI後のDAPT期間について #108PCI後のDAPTは以前は長い期間(1年)と言われていましたが、最近はステントの進化により、より短い期間でも血栓リスクを抑えることができるようになってきているようですね。ただ患者さんの病態などで期間は個々によって変わってきますので、注意が必要です。
---
stand.fmでは、この放送にいいね・コメント・レター送信ができます。
https://stand.fm/channels/60a9276ab82bc5e1f3e12509
2025-08-2312 min
JACC Deep DiveMaster DAPT | JACC Deep DiveIn this episode of JACC Deep Dive, Dr. Harlan Krumholz explores new insights from a post hoc analysis of the MASTER DAPT trial, highlighting the real-world burden of ischemic and bleeding events in high bleeding risk patients after PCI. By examining recurrent—not just first—events, the study sheds light on how abbreviated dual antiplatelet therapy (DAPT) impacts total clinical outcomes. Key findings include reduced bleeding without increased ischemic risk and a notable clustering of ischemic events following bleeding. This analysis advances the conversation around patient-centered endpoints and the evolving science of recurrent event modeling in cardiology.
2025-08-1107 min
JACC This WeekDevice Safety, DAPT Strategy & Structural Innovation | JACC This WeekIn this episode of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz explores device safety, abbreviated DAPT, drug-coated balloons, and a novel surgical polymer valve. Plus: expert insights on cardiovascular innovation, obesity management, fellowship signaling, and more.
2025-08-1118 min
Star Update Podcast - Cardiology News SummariesAntiplatelet and Anticoagulant Therapy in the 2025 ACC/AHA Guideline for Acute Coronary Syndromes: Key RecommendationsAntiplatelet and Anticoagulant Therapy in the 2025 ACC/AHA Guideline for Acute Coronary Syndromes: KeyRecommendationsJACC. 2025 Jun, 85 (22) 2074–2078 The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for theManagement of Patients With Acute Coronary Syndromes (ACS), published in this issue of JACC, replaces the prior U.S. guidelines on the management of ST-segment and non–ST-segment elevation ACS. The new guideline provides anexcellent evidence-based framework for diagnosis and management of type I ACS (ie, in the setting of atherothrombosis). This Guideline Commentary highlightsthe key recommendations related to antithrombotic therapy, compares the 2025 guideline with prior American College of Cardiolo...
2025-06-3003 min
PodGAS: An Anesthesia PodcastKeyword: Stents and DAPT (ACC/AHA)This episode of PodGAS was generated using NotebookLM from OpenAnesthesia summaries for the keywords stent management and DAPT.
2025-06-0818 minStar Update Podcast - Cardiology News SummariesAspirin vs Clopidogrel vs Ticagrelor Monotherapy Compared to 12 Months of DAPT Following PCI; A Systematic Review and Meta-AnalysisAspirin vs Clopidogrel vs Ticagrelor Monotherapy Compared to 12 Months of DAPT Following PCI; A Systematic Review and Meta-AnalysisDOI: 10.1016/j.jscai.2025.103158 ExternalLink BackgroundShort-term Dual Antiplatelet Therapy (DAPT) may reduce the risk of bleeding after Percutaneous Coronary Intervention (PCI) as compared to the standard 12 months of Dual Antiplatelet Therapy . However, it may not provide the same benefits against stent thrombosis and ischemic events. We aim to analyse the various recent Randomized Controlled trials (RCTs) to find the ideal drug among Aspirin or one of the PGY12 Inhibitors and time of initiation for monotherapy fol...
2025-05-3102 min
Almost Like We Met Connections RadioConnections Radio 019 - Y-DAPTOn this episode, host Tae Taem is joined by Milan-based producer and Disco Pastrami founder Y-DAPT. The show kicks off with a spotlight on new remixes from Almost Like We Met’s "Reconnection" series, all dropping April 11th on every major platform.Since 2017, Y-DAPT has been bending genres—fusing house, electro, breaks, and bass into bold, futuristic club cuts. With releases on labels like Another Rhythm and Farris Wheel, and support from heavyweights like Fatboy Slim, Claptone, and David Guetta, his sound is all about big bass, colorful energy, and pure unpredictability.Tracklist: Tae...
2025-04-0454 min
JACC Specialty JournalsSex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI - JACC: AdvancesDarshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI
2025-02-2602 min
DozeCast - Cardiologia165 - O tempo ideal de Dupla Antiagregação Plaquetária (DAPT): o fim dos 12 meses? - Ft. Dr Luiz Fernando TanajuraSerá que a recomendação clássica de 12 meses de DAPT após SCA ou angioplastia ainda faz sentido? Neste episódio, exploramos as evidências mais recentes que questionam essa prática tradicional.✅ O que você vai ouvir: • Diferenças entre os principais inibidores do P2Y12 (clopidogrel, prasugrel e ticagrelor) • Quando encurtar, descalonar ou estender a DAPT com base nos principais Trials • Como avaliar o risco de sangramento (Scores PRECISE-DAPT e DAPT)• Terapia tripla em pacientes com fibrilação atrial e necessidade de anticoagulaçãoVamos...
2025-02-2058 min
LINNC INR PodcastsMending Minds: Jildaz Caroff's interviewIn this new episode of the Mending Minds podcast series, Dr. Nanthiya Sujijantarat and her guest, Dr. Jildaz Caroff, explore breakthrough techniques and practices shaping the future of medical treatments. Dr. Jildaz Caroff, Le Kremlin-Bicêtre, Paris, shares his expertise on dual antiplatelet therapy (DAPT) following flow-diverter (FD) treatment of intracranial aneurysms. In this new episode, you will learn:DAPT: Current practices after FD treatments for intracranial aneurysms.Surface modifications & shield technology: Impact of coatings on treatment safety and efficacy.The INSPIRE registry: Real-life data on FD treatments using shield technology.D...
2024-12-2008 min
HeartBeat PodcastTicagrelor or Dual Therapy After Stents: Key Insights from the ULTIMATE-DAPT StudyIn this episode, we take an in-depth look at the groundbreaking ULTIMATE-DAPT clinical trial, which examines the safety and efficacy of using ticagrelor alone compared to combining it with aspirin for patients who have undergone stent placement after acute coronary syndromes. We’ll break down the study’s methodology, key findings, and their potential to reshape post-PCI treatment strategies by reducing bleeding risks while maintaining cardiovascular protection. Join us for a clear and insightful discussion on how this research could change the way heart patients are cared for worldwide. A must-listen for anyone interested in the latest advances in card...
2024-11-2410 min
Anesthesia Patient Safety Podcast#229 Revolutionizing Anesthesia Care for Cardiac Patients: Shorter and Safer Dual Antiplatelet Therapy with Next-Gen StentsWhat if the future of dual antiplatelet therapy (DAPT) could be shorter, safer, and more effective? Uncover the latest insights into drug-eluting stents and how they are transforming how we think about dual-antiplatelet therapy. Join us as we examine the game-changing recommendations from top cardiology societies, which suggest that newer-generation stents can significantly reduce the duration of DAPT, particularly for patients with a high bleeding risk. Listen in as we dissect the innovative tools like the PRECISE-DAPT score and ARC-HBR criteria used to determine bleeding risk, ensuring patient safety without compromising on the efficacy of treatment. We delve into...
2024-11-2017 minStar Update Podcast - Cardiology News SummariesShort-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes. A Systematic Review and Network Meta-AnalysisShort-Term Dual Antiplatelet Therapy
After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes. A Systematic Review and Network Meta-Analysis
JAMA Cardiol. Published online October 9, 2024.
doi:10.1001/jamacardio.2024.3216
Abstract
Importance : The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains under debate.
Objectives: To analyze the efficacy and safety of dual antiplatelet therapy strategies in patients with acute coronary syndromes using a bayesian network meta-analysis.
Data Sources : MEDLINE, Embase, Cochrane, and LILACS databases were searched from inception to April 8, 2024.
St...
2024-10-3104 min
Disco Pastrami RadioS02 E01: Disco Pastrami Radio ft. Y-DAPTNew Season is starting off with our selection for the month and an exclusive mix from Y-DAPT!Your Monthly Dance Music Sandwich! In the mix every month with our favourite Electronic Dance Music releases + a guest mix from our DJs. Support the showDisco Pastrami: Your Dance Music Sandwich! One Episode every 2 weeks, with new Editor's choices and 40 min guestmix from our music scene :)
2024-09-191h 00Star Update Podcast - Cardiology News SummariesEfficacy and Safety of P2Y12 monotherapy vs standard dual antiplatelet therapy DAPT in patients undergoing percutaneous coronary intervention: meta-analysis of randomized trialsEfficacy and Safety of P2Y12 monotherapy vs DAPT in patients undergoing percutaneous coronary intervention: meta-analysis of randomized trials
Curr Probl Cardiol. 2024 Aug;49(8):102635. doi: 10.1016/j.cpcardiol.2024.102635
Abstract
Background: Debates persist regarding the optimal duration of dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) in coronary artery disease (CAD). Recent trials have introduced a novel approach involving P2Y12 inhibitor monotherapy with ticagrelor or clopidogrel, after a short dual antiplatelet therapy (DAPT). However, the effectiveness and safety of this strategy remains to be established. We aimed to perform a meta-analysis comparing monotherapy with P2...
2024-08-3102 minStar Update Podcast - Cardiology News SummariesTicagrelor monotherapy in ST-elevation myocardial infarction: An individual patient-level meta-analysis from TICO and T-PASS trialsTicagrelor monotherapy in ST-elevation myocardial infarction: An individual patient-level meta-analysis from TICO and T-PASS trials
Med. 2024 Aug 10:S2666-6340(24)00301-5.
doi: 10.1016/j.medj.2024.07.019.
Abstract
Background: Patients with ST-elevation myocardial infarction (STEMI) tend to be excluded or under-represented in randomized clinical trials evaluating the effects of potent P2Y12 inhibitor monotherapy after short-term dual antiplatelet therapy (DAPT).
Methods: Individual patient data were pooled from randomized clinical trials that included ST-elevation myocardial infarction STEMI patients undergoing drug-eluting stent (DES) implantation and compared ticagrelor monotherapy after short-term (≤3 months) short-term
dual antiplatelet therapy versus ticagrelor-based 12-mont...
2024-08-3102 min
The First CustomerThe First Customer - Shifting Tech Landscapes through Digital Drift with CEO and Founder Jim KeeneyIn this episode, I was lucky enough to interview Jim Keeney, founder and CEO of Dapt Tech.Jim explains that the entrepreneurial drive is fueled by a desire to build things and solve problems, which began for him in childhood. He talks about how Dapt Tech helps businesses track profit and loss by activity, allowing them to accurately assess the costs of specific jobs and make informed decisions about future projects. Jim also shares his background in software development and how his experience with Fitterweb Consulting led to the creation of Dapt Tech.Jim highlights...
2024-08-1925 min
The Lead Podcast presented by Heart Rhythm SocietyThe Lead Podcast - Episode 72Deepthy Varghese, MSN, ACNP, FNP, Northside Hospital is joined by Hung-Fat Tse, Sr., MD, University of Hong Kong and Glenn Young, MBBS, Royal Adelaide Hospital to discuss the effectiveness of the PRECISE-DAPT score with the CHA2DS2VASC score in predicting thromboembolic risk in nonvalvular atrial fibrillation (AF) patients undergoing transesophageal echocardiography (TEE) before AF ablation. 428 patients were analyzed, with 60 in the thrombogenic positive group and 368 in the thrombogenic milieu negative group. Multivariate logistic regression revealed that the PRECISE-DAPT score independently predicted thrombogenic milieu presence (OR: 1.145, CI: 1.083–1.211, p < > https://www.hrsonline.org/education/TheLead htt...
2024-08-0115 min
BaladoCritique - club de lecture médicalBC 063 – Dé-escalade de la thérapie antiplaquettaire double avec ticagrélor seul post-syndrome coronarien aigu (étude ULTIMATE-DAPT)Dans cette 63e baladodiffusion, les Dr Luc Lanthier et Étienne Couture discutent de l’utilisation de la thérapie antiplaquettaire post-syndrome coronarien aigu, en plus de réviser la littérature médicale de mai 2024.
Quiz clinique (3 min 25), présentation principale (3 min 57), critique (27 min 00), autres articles (35 min 41), réponse au quiz clinique (38 min 12)
Référence principale :
Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, et al; ULTIMATE-DAPT investigators. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary inter...
2024-06-1900 min
The Rounds TableEpisode 87 - The ULTIMATE-DAPT Trial and Empagliflozin after Acute Myocardial InfarctionSend us a textWelcome back Rounds Table Listeners!We are back today with our Classic Rapid Fire Podcast!This week, Drs. Mike and John Fralick discuss two recent papers exploring the role of ticagrelor with aspirin versus ticagrelor alone after percutaneous coronary intervention in acute MI and the efficacy of empagliflozin after acute MI. Two papers, here we go!Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT) (0:00 – 9:22). Empagliflozin after Acute Myocardial Infarction (9:22 – 16:00).And for the Good Stuff:Imp...
2024-06-0619 minThe Rounds TableEpisode 87 - The ULTIMATE-DAPT Trial and Empagliflozin after Acute Myocardial InfarctionSend us a textWelcome back Rounds Table Listeners!We are back today with our Classic Rapid Fire Podcast!This week, Drs. Mike and John Fralick discuss two recent papers exploring the role of ticagrelor with aspirin versus ticagrelor alone after percutaneous coronary intervention in acute MI and the efficacy of empagliflozin after acute MI. Two papers, here we go!Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT) (0:00 – 9:22). Empagliflozin after Acute Myocardial Infarction (9:22 – 16:00).And for the Good Stuff:Imp...
2024-06-0619 minStar Update Podcast - Cardiology News SummariesTicagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT)Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomized, placebo-controlled, double-blind clinical trial
Randomized Controlled Trial Lancet . 2024 May 11;403(10439):1866-1878. doi: 10.1016/S0140-6736(24)00473-2.
Abstract
Background: Following percutaneous coronary
intervention with stent placement to treat acute coronary syndromes, international clinical guidelines generally recommend dual antiplatelet therapy
with aspirin plus a P2Y12 receptor inhibitor for 12 months to prevent myocardial infarction and stent thrombosis. However, data on single antiplatelet therapy with a potent P2Y12 inhibitor earlier than 12 months a...
2024-05-3104 min
Clube da Cardio Podcast128 - KARDIA, ULTIMATE-DAPT E PREVENT - ACC 2024 - Highlights do Congresso Americano de CardiologiaSend us a textO congresso americano de Cardiologia aconteceu no começo de abril e a gente fica naquela expectativa de ler e observar as discussões conforme os trabalhos são apresentados. O Clube já enviou a primeira parte da análise dos principais trials pela Newsletter, se você não está inscrito, não perca a chance de receber no seu e-mail as novidades da Cardiologia! Nessa segunda parte do episódio deCobertura dos destaques do ACC 2024 Luís Augusto convida André Feldman e Guilherme Arruda para conversar sobre os estudo...
2024-04-1258 min
Medical Digest & Congress ReportULTIMATE-DAPT: Most Patients With ACS Can Safely Stop Aspirin One Month Post PCI - report from ACC2024Professor Gregg W. Stone shared his insights on the ULTIMATE-DAPT study. Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.
Video: https://medicaldigest.org/scientific-contents/interview:ultimate-dapt-most-patients-acs-can-safely-stop-aspirin-one-month-post-pci
2024-04-1206 minStar Update Podcast - Cardiology News SummariesP2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical TrialP2Y12 Inhibitor Monotherapy vs Dual
Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial
JAMA Netw Open. 2024 Mar 4;7(3):e240877
Abstract
Importance: P2Y12 inhibitor monotherapy after dual
antiplatelet therapy (DAPT; a P2Y12 inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for patients undergoing percutaneous coronary intervention with a drug-eluting stent.
Objective: To investigate whether P2Y12 inhibitor
monotherapy after 3 months of DAPT
was noninferior to 12 months of DAPT following percutaneous coronary intervention with a drug-eluting stent.
Design, set...
2024-03-3104 min
Questioning Medicine248. Should DAPT To Be Started >24hours After Minor Stroke OR High Risk TIA?Even when starting DAPT within 72hours of symptom onset for individuals with minor stroke or TIA the benefit of DAPT for the first 21 days was still seen at 90 day follow up in the form of less recurrent strokehttps://www.nejm.org/do/10.1056/NEJMdo007334/full/
2024-02-2805 minStar Update Podcast - Cardiology News SummariesOne year clinical outcome of dual anti-platelet therapy with the Novel Ticagrelor plus Aspirin versus Clopidogrel plus Aspirin for Endovascular Intervention of patients with Intracranial AneurysmOne year clinical outcome of dual anti-platelet therapy with the Novel Ticagrelor plus Aspirin versus Clopidogrel
plus Aspirin for Endovascular Intervention of patients with Intracranial Aneurysm: A meta-analysis
J Stroke Cerebrovasc Dis. 2024 Jan;33(1):107491.
Abstract
Background: The use of stents to treat un-ruptured
intracranial aneurysms was first approved in the year 2002 in the United States as a Humanitarian Device Exemption. Antiplatelet therapy is mandatory following stent placement. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel
has been the first line agents for the prevention of thromboembolic events following neuro-endovascular procedures. However, clopidogrel hypo-responsiveness has...
2024-01-3104 minStar Update Podcast - Cardiology News SummariesDe-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in East Asian Patients With Acute Coronary SyndromeDe-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in East Asian Patients With Acute
Coronary Syndrome
Clin Ther. 2023 Dec 8:S0149-2918(23)00305-3.
doi: 10.1016/j.clinthera.2023.08.004
Abstract
Purpose: East Asian individuals have a lower risk of thromboembolic events while potentially carrying a higher risk
of bleeding events compared with non-Asian individuals. The aim of the present analysis was to investigate the effectiveness and safety of the de-escalation of antiplatelet therapy compared with standard dual antiplatelet therapy (DAPT)
in East Asian patients undergoing percutaneous coronary intervention (PCI).
Methods: Randomized control...
2023-12-3102 min
Emergency Medical MinutePodcast 882: Thrombolytics for Minor StrokesContributor: Aaron Lessen MD Educational Pearls: How is the severity of a stroke assessed? Strokes are assessed by the NIH Stroke Scale (NIHSS), this scale has different tasks, such as asking the person to repeat words, move their arms, or follow simple instructions. The maximum score is 42 but any score over 21 is considered severe. What would qualify as a minor storke? NIH
2023-12-2002 minStar Update Podcast - Cardiology News SummariesShort-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-AnalysisShort-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis
Circ Cardiovasc Interv. 2023 Sep;16(9):e013242
Abstract
Background: Short-term (≤6 months) dual antiplatelet
therapy (DAPT) and DAPT de-escalation become attractive for patients with acute coronary syndrome.
Methods: A systemic search identified randomized
controlled trials that included patients with acute coronary syndrome treated using (1) standard DAPT (12 months) with clopidogrel, prasugrel (standard/low dose), or ticagrelor; (2) extended DAPT (≥18 months); (3) short-term DAPT (≤6
months) followed by P2Y12 inhibitor or aspirin; (4) 12-month DAPT with unguided de-escalation from potent...
2023-09-3003 min
Talking PointsMASTER DAPT: Long-Term ResultsMarco Valgimigli and C. Michael Gibson discuss the long-term follow-up results from MASTER DAPT, which compared the outcomes of high bleeding risk patients randomized to either abbreviated or standard antiplatelet therapy.
2023-09-1305 min
2023-09-0202 min
Nathan Bohncast PodcastStarting Up a Startup with Adam BabbitAdam Babbit is the Chief Technology Officer of Dapt, a B2B SaaS solution to track job and project costs. Dapt connects Accounting, Time Tracking, and Payroll to simplify payroll and accounting and meet compliance requirements. He's built out a full development team from the ground up, and helmed all things software for the company for nearly 2 years.
Despite this, Adam is only 24. He was hired by Dapt as a software dev right out of university, and quickly filled both a technical and leadership vacuum, entering the C-suite after just a few months.
2023-05-2643 minStar Update Podcast - Cardiology News SummariesSex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarctionSex-stratified differences in early antithrombotic
treatment response in patients presenting with ST-segment elevation myocardial
infarction
Am
Heart J 2023 Apr; 258:17-26 doi: 10.1016
Background: The mechanisms underlying the increased risk of bleeding that
female patients with ST-segment Elevation Myocardial Infarction (STEMI)
exhibit, remains unclear. The present report assessed sex-related differences
in response to pre-hospital dual antiplatelet therapy (DAPT) initiation in
patients with STEMI.
Methods: The COMPARE CRUSH trial randomized patients presenting with
STEMI to receive a pre-hospital loading dose of crushed or integral prasugrel
tablets in the ambulance. In this substudy, we compared platelet reactivity
lev...
2023-05-0202 minStar Update Podcast - Cardiology News SummariesSex-related bleeding risk in acute coronary syndrome patients receiving dual antiplatelet therapy with aspirin and a P2Y12 inhibitorSex-related bleeding risk in acute coronary syndrome patients receiving dual antiplatelet therapy with aspirin and a P2Y12 inhibitor
Med Princ Pract. 2023 Mar 22.
Abstract
Aims To study sex differences in major bleeding in relation to dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods and results The Collective Cardiology Research registry was designed to evaluate the application and outcomes of DAPT after ACS/PCI in the Rijnmond region in the Netherlands. Overall, 1172 women (median age 67.5 years) and 3087 men (62.2 years) with ACS/PCI were enrolled...
2023-03-3002 min
2023-03-2904 min
BackTable Vascular & InterventionalEp. 301 New Technologies for Treatment of Cerebral Aneurysms with Dr. David Altschul and Dr. Omar TanweerIn this episode, host Dr. Sabeen Dhand speaks with neurosurgeons Drs. David Altschul and Omar Tanweer about updates on cerebral aneurysms, including device innovation, risk stratification, and the importance of the doctor-patient relationship in decision-making.---CHECK OUT OUR SPONSORMicroVention FRED Xhttps://www.microvention.com/emea/product/fred-x---SHOW NOTESDr. Omar Tanweer is the director of cerebrovascular and endovascular neurosurgery at Baylor College...
2023-03-1339 min
ESC TV Today – Your Cardiovascular NewsAmong the topics: Cardiac involvement in Fabry’s disease - Anti-thrombotic therapy post PCI: DAPT in 2023ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Cardiac involvement in Fabry’s Disease Anti-thrombotic therapy post PCI: DAPT in 2023 Mythbusters: Powernap for heart health Host: Rick Grobbee Guests: Perry Elliott, Nicolle Kraenkel, Roxana Mehran and Franz Weidinger Want to watch that episode? Go to: https://esc365.escardio.org/event/896 Disclaimer This programme is intended for health care professionals onl...
2023-02-0919 minStar Update Podcast - Cardiology News SummariesTicagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney diseaseAbstract
Background: No study has compared pharmacologic properties of ticagrelor and clopidogrel in non-dialysis patients with stage 4-5 chronic kidney disease (CKD).
Methods: We conducted a double-blind RCT to compare effects of ticagrelor and clopidogrel in 48 CKD, with the primary outcome of ADP-induced platelet aggregation (WBPA) after 2 weeks of DAPT. In a parallel arm, we compared effects of 2 weeks of ticagrelor plus aspirin on mean changes in WBPA and markers of thromboinflammation among non-CKD controls (n = 26) with that of CKD in the ticagrelor-arm.
Results: Average age of CKD was 53.7 years, with 62% women, 54% African...
2023-01-3102 minStar Update Podcast - Cardiology News SummariesTreatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysisTreatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis
Abstract:
Introduction: Type 2 diabetes mellitus (T2DM) is a risk factor for the development of coronary artery disease (CAD). In patients with acute coronary syndrome (ACS), guidelines recommend a potent P2Y12 inhibitor in addition to aspirin. For those with complicated and advanced CAD requiring complex percutaneous coronary intervention (PCI), the risk for adverse ischemic events is even higher. Prolonged dual antiplatelet therapy (DAPT) use is controversial. A new antiplatelet regimen after...
2022-12-2603 min
Mayo Clinic Pharmacy Grand RoundsDual Antiplatelet Therapy Following PCI: Choosing a SMART-DATE to STOP-DAPTKyle A. Hess, PharmD (Twitter: @KyleHessPharmD ) describes current guideline recommendations for duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention, compares and contrasts strategies for antiplatelet regimens for reduced duration DAPT and selects an appropriate duration of therapy when utilizing shortened DAPT.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
2022-10-0531 minStar Update Podcast - Cardiology News SummariesSafety and efficacy of dual antiplatelet therapy combining aspirin and ticagrelor in patients with undergoing intracranial stenting proceduresAbstract
Background: Thromboembolic complications are one of the major periprocedural complications following neuroendovascular procedures. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel remain the principal agents for prevention of thromboembolic complications. However, clopidogrel resistance is associated with higher risk of thromboembolic complications. This study investigated the safety and efficacy of DAPT with ticagrelor and aspirin in patients undergoing intracranial stenting procedures.
Methods: This retrospective study was based on patients with intracranial aneurysms who undergoing intracranial stenting procedures at our institution between August 2017 and July 2020. These patients received DAPT with ticagrelor and aspirin were included. DAPT...
2022-10-0402 minMedical Digest & Congress ReportGuidelines in Practice: dual antiplatelet therapy (DAPT) - report from ESC2022Professor Robert Storey co-chaired a very interesting Guidelines in Practice session on dual antiplatelet therapy at this year’s ESC Congress. The session was started with a case presentation of a patient undergoing complex PCI for NSTE-ACS with high risk both for bleeding and trombotic complications.
Video: https://congressreport.eu/scientific-contents/interview:guidelines-practice-dual-antiplatelet-therapy-dapt
2022-09-0211 min
DozeCast - Cardiologia044 - Sangramento e Síndrome coronariana aguda - Ft. Dr Louis Ohe🎙 Imagine um paciente com HDA recente que chega no pronto-socorro com IAM. Ou que teve um IAM recente com colocação de stent, está com DAPT e evolui com sangramento importante. O que fazer nessas situações?
🩸 O antagonismo entre risco isquêmico pós angioplastia e risco de sangramento com a dupla antiagregação plaquetária envolve diversos aspectos a serem debatidos e, para isso, Mateus Prata e Diandro Mota contam com um brilhante convidado: Dr Louis Nakayama Ohe.
👨🏼⚕️ Dr. Louis é médico formado pela EPM, cardiologista e hemodinamicista pelo Instituto Dante Pazzanese de Cardiologia. Foi diretor do pr...
2022-07-2845 min
Star Update Podcast - Cardiology News SummariesTicagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBRPatients at a high risk of bleeding (HBR) are a common subgroup of those receiving percutaneous coronary intervention (PCI). After a short period of dual antiplatelet treatment (DAPT), early aspirin discontinuation has emerged as a bleeding prevention technique. It has been demonstrated by TWILIGHT trial that ticagrelor monotherapy is an effective and safe bleeding prevention approach for high-risk PCI patients, following a short course of DAPT.
TWILIGHT-HBR was conducted with the pre-specified analysis of TWILIGHT trial to determine the treatment effects of ticagrelor monotherapy compared with ticagrelor plus aspirin in a contemporary high-bleeding risk group. In this...
2022-05-3101 min
Cardionerds: A Cardiology Podcast211. Case Report: A Zebra in Polka Dots – Coronary Intervention With Glanzmann Thrombasthenia – UCLACardioNerds (Amit and Dan) join Dr. Omid Amidi (CardioNerds Academy Graduate) and Dr. Marwah Shahid from the UCLA Cardiology Fellowship program along with Dr. Evelyn Song (CardioNerds Academy House Faculty and Heart Failure Hospitalist at UCSF) to discuss a complex case focused on management of severe coronary artery disease in a patient with Glanzmann thrombasthenia. Dr. Rushi Parikh (Interventional cardiologist, UCLA) provides the ECPR for this episode. Audio editing by CardioNerds Academy Intern, student doctor Akiva Rosenzveig.
Glanzmann Thrombasthenia is a bleeding disorder due to impairment of platelet aggregation secondary to a mutation in the GPIIB/IIIA receptor. This case is...
2022-05-2935 min
Star Update Podcast - Cardiology News SummariesEffect of Ticagrelor Monotherapy vs Ticagrelor with Aspirin on Major Bleeding and Cardiovascular Events in Patients with Acute Coronary Syndrome: The TICO Randomized Clinical TrialIn the TICO randomized clinical trial, stopping aspirin was tested as a bleeding reduction method after short-term dual anti-platelet treatment (DAPT). However, ticagrelor monotherapy has not been studied in patients with acute coronary syndromes solely (ACS). The objective of this study was to determine whether moving to ticagrelor monotherapy in patients with ACS treated with drug-eluting stents, after 3 months of DAPT lowers net adverse clinical events compared to ticagrelor-based 12-month DAPT.
This randomized controlled trial was conducted in 3056 patients with ACS treated with drug-eluting stents between August 2015 and October 2018 were included in this trial. The patients were...
2022-05-2702 min
This Week in CardiologyMay 20, 2022 This Week in Cardiology PodcastIschemia vs anatomic testing for CAD, UK-TAVI trial, TAVI for AR? and post-PCI anti-thrombotics are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I – Ischemic vs Anatomic Evaluation for CAD - ISCHEMIA Substudy Data Just Don't Add Up, Cardiac Surgeons Say https://www.medscape.com/viewarticle/974107 - Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.049755 ...
2022-05-2024 minCardionerds: A Cardiology Podcast205. Guidelines: 2021 ESC Cardiovascular Prevention – Question #11 with Dr. Eugenia GianosThe following question refers to Section 6.1 of the 2021 ESC CV Prevention Guidelines. The question is asked by Dr. Christian Faaborg-Andersen, answered first by UCSD cardiology fellow Dr. Harpreet Bhatia, and then by expert faculty Dr. Eugenia Gianos.
Dr. Gianos specializes in preventive cardiology, lipidology, cardiovascular imaging, and women’s heart disease; she is the director of the Women’s Heart Program at Lenox Hill Hospital and director of Cardiovascular Prevention for Northwell Health.
The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardi...
2022-05-1208 min
Star Update Podcast - Cardiology News SummariesDAPT Discontinuation, Platelet Reactivity, and Adverse Outcomes After PCiThis post hoc analysis of the ADAPT-DES study investigated the predictors of dual antiplatelet therapy (DAPT) discontinuation, associations between different types and timing of DAPT discontinuation with thrombotic events, and the impact of on-treatment high platelet reactivity in 8582 patients who were already receiving aspirin and clopidogrel after undergoing PCI.
In result it was seen that approximately 50% of patients discontinued DAPT within 2 years, with unplanned DAPT discontinuation occurring in 16.5% of patients and discontinuation of both aspirin and clopidogrel occurring in 29.8% of patients.
Also, unplanned discontinuation was associated with a significantly increased risk of a major adverse...
2022-05-0402 min
Last Week in MedicineOral Carbapenem for Complicated UTIs, Awake Proning for COVID-19, 1-2 Months DAPT vs 12 Months DAPT, Low Sodium Diet for Heart Failure, Excess Mortality From COVID-19, IV Iron and Anaphylaxis, Pickle Juice for Cramps in CirrhosisDr. Brian Locke is back to talk about that "nonrandomized" proning trial. We also talk about the new oral carbapenem for UTI trial, whether 1-2 months of DAPT is non-inferior to 12 months of DAPT, whether less than 1500 mg of sodium reduces heart failure hospitalizations, the risk of anaphylaxis from IV iron, and whether pickle juice is effective for treating cramps in cirrhosis. Check it out! Oral Tebipenem vs IV Ertapenem for Complicated UTIAwake Proning for Hospitalized COVID-19 Patients1-2 Months of DAPT vs 12 months of DAPT vs ACSLow Sodium Diet for Heart F...
2022-04-2350 minTalking PointsEpisode 144: MASTER DAPT: High-Risk PatientsC. Michael Gibson and Pieter C. Smits review outcomes in high-bleeding-risk patients also at high risk for thrombotic events who were randomized to abbreviated DAPT.
2022-04-2006 min
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio PodcastGregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to...
2022-04-161h 26
PeerView Internal Medicine CME/CNE/CPE Audio PodcastGregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to...
2022-04-161h 26
PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastGregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to...
2022-04-161h 26
PeerView Internal Medicine CME/CNE/CPE Video PodcastGregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to...
2022-04-161h 26
PeerView Clinical Pharmacology CME/CNE/CPE VideoGregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to...
2022-04-161h 26
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastGregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to...
2022-04-161h 26
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video PodcastGregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to...
2022-04-161h 26
PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastGregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to...
2022-04-161h 26
DozeCast - Cardiologia022 - DAPT: além do AAS e Clopidogrel na síndrome coronariana agudaMarcos Meniconi, Maria Julia Souto e Manuela Gomes analisam os fatores que devem influenciar o cardiologista a definir quais antiagregantes plaquetários e quanto tempo de terapia dupla deve ser indicado para o paciente submetido a angioplastia coronária percutânea. Acompanhe para recordar os “landmark trials” e novidades sobre o tema.
Minutagem:
(01:45): tipos de antiagregantes plaquetários
(03:15): resistência genética ao clopidogrel?
(05:45): quando o segundo antiagregante deve ser o clopidogrel
(07:16): ataque do antiagregante na emergência
(12:45): por quanto tempo manter a DAPT?
(18:22): da para reduzir o tempo de DAPT?
(21:20): o que vem por aí (NEO-MINDSET trial)
(23:00): mensagens finais
(24:30): resposta aos...
2022-02-1727 minThis Week in CardiologyFeb 11, 2022 This Week in Cardiology PodcastLDL equations, stroke interventions, post-PCI antiplatelets, the transitive function and network meta-analysis, and lipoprotein(a) are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I - LDL-C Equations: - Standard LDL Equations Yield Discordant Results https://www.medscape.com/viewarticle/968112 - Discordance Between Standard Equations for Determination of LDL Cholesterol in Patients With Atherosclerosis https://www.jacc.org/doi/10.1016/j.jacc.2021.11.042 - LDL-C Estimation: The Perils of...
2022-02-1120 minStar Update Podcast - Cardiology News SummariesGastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet TherapyPatients who undergo percutaneous coronary intervention (PCI) with drug-eluting stents require dual antiplatelet therapy (DAPT) for at least 6 months for stable ischemic heart disease (SIHD) or 12 months for acute coronary syndromes (ACS) to prevent stent thrombosis and other cardiovascular events (1).
The rationale for using DAPT is that aspirin and a P2Y12 antagonist (such as clopidogrel, prasugrel, or ticagrelor) separately inhibit the c (COX-1) and the adenosine diphosphate–dependent pathways, and together confer greater protection against platelet activation and stent thrombosis than either antagonist alone. Unfortunately, DAPT approximately doubles the risk of gastrointestinal (GI) bleeding compared with si...
2022-01-3106 min
ドクターサロン「DAPT（抗血小板薬2剤併用療法）」（211221放送）「DAPT（抗血小板薬2剤併用療法）」（解説）昭和大学 循環器内科学 主任教授 新家俊郎氏（ききて）防衛医科大学校教授 池脇克則氏
2021-12-2800 minStar Update Podcast - Cardiology News SummariesReal-World’ Prolonged DAPT Use Associated With Reduced Benefits, and Greater Harm Prolonged use of dual antiplatelet therapy (DAPT) following PCI may be associated with reduced benefits and greater harms in “real-world” clinical practice in contrast to outcomes of the DAPT Study
The study included 8,864 patients from the DAPT study and 568,540 registry patients. Longer-duration P2Y12 inhibitor therapy in the DAPT cohort was associated with a 1.01% decrease in-stent thrombosis, 1.9% decrease in major adverse cardiac and cerebrovascular events and a 2.27 decrease in MI but a 0.89% increase in moderate or severe bleeding.
The study concludes that longer-duration DAPT may have more limited benefits and greater harms when applied broadly in a...
2021-12-0301 min
CardioScripts PodcastThe MASTER DAPT TrialDr. Ashley Schenk discusses the MASTER DAPT trial with co-host, Dr. Liz Wang.
2021-11-2320 min
Medical DialoguesOne month dual antiplatelet therapy non inferior to standard regimens- MASTER DAPT TRIALProlonged dual antiplatelet therapy is the treatment of choice for patients with acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) with a drug-eluting stent. The rationale is anchored in the understanding that drug-eluting stents impair the vascular healing process because exposure of the metal in the stent serves as a nidus for stent thrombosis. But the ideal duration of this therapy is still a gray area for stable angina patients undergoing PCI. The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. Researchers have...
2021-11-1102 min
Practice Impact Extra89 Dapt - 2 ACS TrialIn acute coronary syndrome is a short or long-term DAPT strategy best?
2021-11-0203 minStar Update Podcast - Cardiology News SummariesTicagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBRPatients at high bleeding risk represent a prevalent subgroup among those undergoing percutaneous coronary intervention. Early aspirin discontinuation after a short course of dual antiplatelet therapy (DAPT) has emerged as a bleeding avoidance strategy.
The aim of this study was to assess the effects of ticagrelor monotherapy in reducing the incidence of primary endpoint of 2, 3, or 5 BARC bleeding after 3-month dual antiplatelet therapy in a contemporary high bleeding risk population.
Event-free patients were randomized to 12 months of aspirin or placebo in addition to ticagrelor, after 3 months of ticagrelor plus aspirin.
At the end...
2021-11-0203 min
Circulation on the RunCirculation October 12, 2021 IssuePlease join author Milton Packer and Associate Editor Justin Ezekowitz as they discuss the Perspective "Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the Journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. ...
2021-10-1127 minThis Week in CardiologySep 24, 2021 This Week in Cardiology PodcastDual antiplatelet therapy after PCI, statin side effects, nightshift work and AF, and a cautionary note regarding therapeutic enthusiasm in HF care are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I - COVID - Alaska Sets Record for Daily COVID Cases https://www.medscape.com/viewarticle/958999 II - MASTER DAPT - MASTER DAPT: 1 Month DAPT Enough After High-Bleeding-Risk PCI https://www.medscape.com/viewarticle/957463 - Antiplatelets and Anticoagulation Post-PCI: More on MA...
2021-09-2426 minStar Update Podcast - Cardiology News SummariesHighlights of ESC Congress 2021: Master DAPTIn a Hot Line session of 28th August, Professor Marco from Switzerland presented results from the investigator-initiated, open-label MASTER DAPT trial comparing an abbreviated vs. a standard duration of antiplatelet therapy after bioresorbable polymer-coated sirolimus-eluting stent implantation in patients with acute or chronic coronary syndrome who fulfilled one or more high bleeding-risk criteria.
Following a mandatory 30-day DAPT run-in phase after percutaneous coronary intervention (PCI), eligible patients who were free from ischaemic and bleeding events were randomized 1:1 to receive abbreviated or standard DAPT.
Abbreviated treatment comprised single antiplatelet therapy until study completion, except for patients...
2021-09-0603 min
Primary Care UpdateEpisode 84: adenotonsillectomy in kids with OSA, DAPT vs ASA for stroke prevention, and ovarian cancer screeningThis week Kate, Henry and Mark give John the week off and discuss outcomes after adenotonsillectomy in children with OSA, the effectiveness and safety of DAPT vs ASA for secondary stroke prevention, and the final results of the largest trial of screening for ovarian cancer using CA-125 and ultrasound.
2021-08-1928 minStar Update Podcast - Cardiology News SummariesMeta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary StentingThis study was aimed to evaluate if a shorter course of Dual Anti-Platelet Therapy followed by P2Y12 inhibitor monotherapy is as effective as a 12-month course with fewer bleeding events.
Five randomized clinical trials were included, with a total of 18,046 participants.
Antiplatelet strategies compared were
· aspirin and P2Y12 inhibitor for 12 months
· aspirin and P2Y12 inhibitor for 1 to 3 months followed by P2Y12 inhibitor alone.
In the end of the study it was found that Patients randomized to 1 to 3 months of DAPT followed by P2Y12 inhibitor mo...
2021-07-3101 min
#HeavyBeats By AdamKHeavy Beats 0721 HBHH - Y - DAPT
HeavyBeats HeavyHitters is our chance to hand the decks over to amazing talent that exists within our industry.
This month’s HeavyBeats HeavyHitters episode is in human! Welcome Y-DAPT. Listen for the details all stacked at the start of the mix.We’re unsure of which planet Y-Dapt comes from and what kind of pronoun to use, so we will stick with an adverb to describe the mix as Heavy-laden. Load it up and play it loud.
Make your suggestion for future HeavyHitters Info@HeavyBeats.Co.Uk
Message us if you like what you hear @HeavyBeats and Follow us...
2021-07-081h 02
Cardio_Cast006-Triple therapyIn the second part of the short DAPT, we review triple therapy in CAD patients, join us for this informative episodeyou can also download the slides with the following link:http://ecardiocast.com/wp-content/uploads/2021/04/Short-DAPT-2nd-episode.pdf
2021-04-3025 minStar Update Podcast - Cardiology News SummariesThe Future of Aspirin Therapy in Cardiovascular DiseaseAspirin is an affordable, familiar, and most widely prescribed drug for acute and post cardiovascular events or revascularization procedures. It is also an essential member of dual antiplatelet therapy or DAPT (a P2Y12 inhibitor plus ASA) and dual pathway inhibition or DPI (Rivaroxaban plus ASA), and data for both combinations are increasing.
Gastrointestinal bleeding is the most common adverse event associated with Aspirin therapy, the COGENT trial has shown that prophylactic PPI agents reduced this risk in Clopidogrel plus Aspirin DAPT therapy. Recently, phospholipid-coated formulation of ASA has been studied in comparison to regular uncoated ASA...
2021-04-1902 min
Core IM | Internal Medicine Podcast#85 Dual Antiplatelet Therapy: 5 Pearls SegmentHow does cost, potency, and bleeding risk affect which antiplatelet you choose P2Y12 inhibitors? How long after starting, do you feel comfortable stopping DAPT on a patient? How do you manage DAPT in patients who need anticoagulation?Show notes, Transcript and References: https://www.coreimpodcast.com/2021/04/07/5-pearls-on-dual…platelet-therapy/Join Our TeamTime stamps02:35 Indications08:52 Medications17:37 Duration28:23 De-escalation30:55 AnticoagulationTags: IM Core, CoreIM, anticoagulation, DAPT, acute coronary syndrome, stents, thrombosis, bleeding risk, cardiology, hospitalist, primary careFind the best disability insurance for you: https://www.patternlife.com/disability-insurance?ca...
2021-04-0735 minCardio_Cast005-Short Duration DAPT- 1st episodeIn this episode you will find:Evaluation of short-term DAPT in stable CAD patients after PCIEvaluation of short-term DAPT in ACS patients after PCIHigh-bleeding risk (HBR) patients and short DAPTyou can also download the slides with the following link:http://ecardiocast.com/wp-content/uploads/2021/04/short-DAPT-part1.pdf
2021-04-0425 min
The Curbsiders Internal Medicine Podcast#229 Hotcakes: COVID on steroids, statins over 75, short duration DAPTJoin us for an extra-hot summer episode featuring our critical appraisal expert, Rahul Ganatra MD, MPH @rbganatra. Prepare to marvel as he breaks down his recent tweetorial on the RECOVERY trial of dexamethasone for COVID-19; to gasp as Paul Williams updates us on statins and ASCVD prevention and to be enthralled by the dulcet tones of Matt Watto explaining the latest research on DAPT vs. monotherapy with ticagrelor. Bonus: a new hotcakes rating scale has arrived!
Show Notes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME!
Credits
...
2020-08-1043 minThe Curbsiders Internal Medicine Podcast#229 Hotcakes: COVID on steroids, statins over 75, short duration DAPTJoin us for an extra-hot summer episode featuring our critical appraisal expert, Rahul Ganatra MD, MPH @rbganatra. Prepare to marvel as he breaks down his recent tweetorial on the RECOVERY trial of dexamethasone for COVID-19; to gasp as Paul Williams updates us on statins and ASCVD prevention and to be enthralled by the dulcet tones of Matt Watto explaining the latest research on DAPT vs. monotherapy with ticagrelor. Bonus: a new hotcakes rating scale has arrived!
Show Notes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME!
Credits
...
2020-08-1043 minTalking PointsEpisode 99: EVOLVE Short DAPT: 3-Month DAPT in PatientsC. Michael Gibson and Ajay Kirtane review the results of this single-arm stent study.
2020-07-2202 min
Stroke FM07 What-Up DAPT!?!Key terms: DAPT, Minor stroke, TIA
Hosts: Tess Fitzpatrick, Katherine Sawicka, and Houman Khosravani
Summary:
Monotherapy with antiplatelet
Dual antiplatelet evidence critical appraisal
CHANCE
POINT
2020-04-0531 min
MDedge CardiocastSun sets on longer DAPT after PCI; inactivity boosts post-MI risk Smoking and inactivity are the most powerful lifestyle risk factors after an MI Insufficient activity beats out obesity or above-target LDL cholesterol. Ticagrelor monotherapy tops DAPT for high-risk PCI patients TWILIGHT findings support move to shorter dual-antiplatelet therapy. Panel releases guidelines for red meat, processed meat consumption "This assessment may be excessively pessimistic; indeed, we hope that is the case." Remember that preeclampsia has a ‘fourth trimester’ Delivering the baby doesn’t always cure the hypertension. For more MDedge Podcasts, go to mded...
2019-10-0408 min
MDedge CardiocastContinue using paclitaxel-eluting PAD devicesThis week's top stories in cardiology: FDA Panel: Continue using paclitaxel-eluting PAD Devices, with caveats. Although the benefits of the devices were clear, the panel felt there should be a label change to warn of the late mortality signal seen in a key meta-analysis. Many cardiac cath, electrophysiology lab directors receive big industry payments These payments were substantially higher than those made to local interventional cardiologists and electrophysiologist. Two trials support shorter DAPT DAPT with a twist: Continuing the P2Y12 inhibitor instead of aspirin. Do black p...
2019-06-2807 min
The Curbsiders Internal Medicine Podcast#128 Aspirin Overhyped and OverusedAspirin’ to figure out if ASA can help prevent a heart attack? Interpreting all the new trials doesn’t have to cause chest pain! Join Dr. Ambarish Pandey from UT Southwestern as he helps The Curbsiders ASCEND the mountains of the latest studies to ARRIVE at some well-informed conclusions on the role of aspirin in primary prevention for cardiac events. The team also discusses secondary prevention, aspirin and dual (or triple) antiplatelet therapy, and whether it’s okay to stop giving aspirin to older adults without known CAD (Spoiler alert: it’s okay). ACP members can visit https://acponline.org/curbs...
2018-12-0353 minThe Curbsiders Internal Medicine Podcast#128 Aspirin Overhyped and OverusedAspirin’ to figure out if ASA can help prevent a heart attack? Interpreting all the new trials doesn’t have to cause chest pain! Join Dr. Ambarish Pandey from UT Southwestern as he helps The Curbsiders ASCEND the mountains of the latest studies to ARRIVE at some well-informed conclusions on the role of aspirin in primary prevention for cardiac events. The team also discusses secondary prevention, aspirin and dual (or triple) antiplatelet therapy, and whether it’s okay to stop giving aspirin to older adults without known CAD (Spoiler alert: it’s okay). ACP members can visit https://acponline.org/curbs...
2018-12-0353 min
OUTER BASS Mixcast - Bass House and UK Bass Every WeekVISIONs 10Weekly podcast of the latest dope house beats #basshouse #electrohouse #breaks #ukbass Every Friday @ 3PM GMT, mixed live by @sonnybanksmusic
Tracklist:
Turbulentz, Benvy, Hyphee - Style (feat. Benvy & Hyphee)
Jack Beats, DJ Zinc, MC GQ - Raise it Up
Arridim & JAIKEA - Mosquito
Steff Da Campo, Snoop Dogg - Bang With The O
Moksi - To the Sound
CYMN & Soul Surgery - Pass That Back
Mephi - Cosmic Banana (Original Mix)
Tough Love, Reigns - Hideaway
Carta, Smack, Kris Kiss - Hit The Deck
Moksi - Legit
Castion, Jack & James - Get Low (Extended Mix)
Y-DAPT - Funky Shot
Sebastian...
2018-10-261h 04Talking PointsEpisode 46: DAPT-STEMIC. Michael Gibson gets the details from DAPT-STEMI from Elvin Kedhi.
2018-05-1805 min
Rony RexRexradio #048Rexradio - Episode #048. Original air date 18th Jan 2018. Live on Finland's Bassoradio every other thursday 18:00-19:00 EST (UTC +2). Hosted in Finnish. Forward-looking club music, no limits.
Download: http://bit.ly/rexradio-048
Bassoradio: http://basso.fi/ronyrex
Spotify Playlist: http://bit.ly/rexradio
Tour Dates: http://ronyrex.com/tourdates
http://ronyrex.com
http://facebook.com/itsronyrex
http://twitter.com/itsronyrex
http://instagram.com/itsronyrex
http://mixcloud.com/ronyrex
http://snapchat.com/add/ronyrex
TRACKLIST
01. Youngr x Endor - Give It Up (Club Edit)
02. The Knocks ft. Captain Cuts - House Party (Doorly Afterparty Re-Rub)
03. Tru Fonix ft. Stush - In the...
2018-01-1859 min
JAMA Clinical ReviewsDual Antiplatelet Therapy: Balancing Ischemic and Bleeding RiskFollowing placement of cardiac stents, patients receive dual antiplatelet therapy (DAPT) to prevent stent thrombosis. Prevention of thrombosis is offset by a risk of bleeding. The optimal balance between thrombosis prevention and bleeding risk is not always known. How to go about optimizing DAPT therapy is discussed by Glen Levine, MD, professor of medicine at Baylor College of Medicine in Houston, Texas, and chair of the combined American College of Cardiology/American Heart Association Guideline Committees.
2017-07-1128 min
The European Heart Journal PodcastCommentary: Choosing a perspective on mortality with DAPTCommentary: Choosing a perspective on mortality with DAPT
2016-01-1306 minThe European Heart Journal PodcastCommentary: Choosing a perspective on mortality with DAPTCommentary: Choosing a perspective on mortality with DAPT
2016-01-1306 minThe European Heart Journal PodcastCommentary: Choosing a perspective on mortality with DAPTCommentary: Choosing a perspective on mortality with DAPT
2016-01-1306 minThe European Heart Journal PodcastCommentary: Choosing a perspective on mortality with DAPTCommentary: Choosing a perspective on mortality with DAPT
2016-01-1306 minThe European Heart Journal PodcastCommentary: Choosing a perspective on mortality with DAPTCommentary: Choosing a perspective on mortality with DAPT
2016-01-1306 minThe European Heart Journal PodcastCommentary: Choosing a perspective on mortality with DAPTCommentary: Choosing a perspective on mortality with DAPT
2016-01-1306 min